Polaris GroupTPE:6550 59 PS Ratio is 245.28 as of Jul. 11, 2026, which is 95% below its 10-year median of 4,854.09. GuruFocus rates TPE:6550 with a GF Score™ of 59/100 and a GF Value™ of NT$55.44 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 930 Biotechnology companies, Polaris Group ranks worse than 90.43% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Polaris Group's share price is NT$13.00.
Polaris Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.05. Hence, Polaris Group's PS Ratio for today is 245.28.
Good Sign:
Polaris Group stock PS Ratio (=258.49) is close to 10-year low of 235.85.
The historical rank and industry rank for Polaris Group's PS Ratio or its related term are showing as below:
TPE:6550'
s PS Ratio Range Over the Past 10 Years
Min: 235.85 Med: 4854.09 Max: 33641.58
Current: 245.28
During the past 12 years, Polaris Group's highest PS Ratio was 33641.58. The lowest was 235.85. And the median was 4854.09.
TPE:6550's PS Ratio is ranked worse than 90.43% of 930
companies
in the Biotechnology industry
Industry Median: 9.515
vs TPE:6550: 245.28
Polaris Group revenue growth has slowed down over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Polaris Group was -62.90% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 80.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 42.40% per year.
During the past 12 years, Polaris Group's highest 3-Year average Revenue per Share Growth Rate was 86.60% per year. The lowest was -10.60% per year. And the median was 80.60% per year.
Back to Basics: PS Ratio
Polaris Group (TPE:6550) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Polaris Group PS Ratio Related Terms
Polaris Group PS Ratio Historical Data
* Premium members only.
The historical data trend for Polaris Group's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Polaris Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Polaris Group PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Polaris Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Polaris Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Polaris Group's Share Price of today is NT$13.00. Polaris Group's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.05.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Polaris Group (TPE:6550) has a PS Ratio of 245.28 as of Jul. 11, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Polaris Group and its competitors. This is 95% below median its historical median of 4,854.09. Over the past decade, Polaris Group's PS Ratio has ranged from 235.85 to 33,641.58. According to the industry distribution chart, Polaris Group ranks #841 out of 930 companies in the Biotechnology industry, placing it in the top 90.4%.
Is Polaris Group's PS Ratio too high?
Polaris Group's current PS Ratio of 245.28 is 95% below median its 10-year median of 4,854.09. Over the past 10 years, this metric has ranged from a low of 235.85 to a high of 33,641.58. The Biotechnology industry median PS Ratio is 9.52. Polaris Group's value of 245.28 is 2477.8% above this industry median. Based on the distribution chart, Polaris Group ranks #841 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Polaris Group has a GF Score™ of 59/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Polaris Group's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Polaris Group ranks #841 out of 930 companies for PS Ratio. This places Polaris Group in the lower half of its industry. The industry median PS Ratio is 9.52. Polaris Group's value of 245.28 is 2477.8% above this benchmark. Historically, Polaris Group's own PS Ratio has ranged from 235.85 to 33,641.58 over the past decade. While the company's 10-year median is 4,854.09 vs. the industry median of 9.52, Polaris Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.52, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Polaris Group's current PS Ratio of 245.28 is 2477.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Polaris Group and its competitors. For the Biotechnology industry, the median PS Ratio is 9.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Polaris Group's current PS Ratio is 245.28, which is 95% below median its own 10-year median of 4,854.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaris Group stock overvalued right now?
Based on GuruFocus' analysis, Polaris Group (TPE:6550) is currently considered Possible Value Trap. The stock's GF Value™ is NT$55.44, compared to a current price of NT$13.00 — trading 76.6% below its estimated fair value. The current PS Ratio is 245.28, which is 95% below median its 10-year median of 4,854.09 and 2477.8% above the Biotechnology industry median of 9.52. Polaris Group's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Polaris Group (TPE:6550), the current PS Ratio is 245.28 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Polaris Group (TPE:6550) Overvalued in 2026?
Based on GuruFocus' analysis, Polaris Group stock appears to be undervalued.
The current stock price of NT$13.00 is trading 76.6% below its estimated GF Value™ of NT$55.44.
GuruFocus considers Polaris Group to be Possible Value Trap.
Key valuation signals for TPE:6550:
PS Ratio: 245.28 (95% below median its 10-year median of 4,854.09)
GF Value™: NT$55.44 vs. price of NT$13.00 (76.6% below fair value)
Industry Position: 2477.8% above the Biotechnology median (#841 of 930)
No single metric tells the full story. See the TPE:6550 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process.
59GF Score
Get the complete analysis for TPE:6550
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6550 has been successfully added to your 
